Document is current

Article History

Received: 12 July 2024

Accepted: 24 October 2024

First Online: 26 November 2024

Declarations

:

: Yoshiya Tanaka received speaking fees and/or honoraria from AbbVie; Asahi Kasei; AstraZeneca; Astellas Pharma; Boehringer Ingelheim; Chugai; Daiichi Sankyo; Eisai; Eli Lilly; Gilead Sciences, Inc.; GSK; Pfizer; Taisho; and UCB, and received research grants from Chugai, Boehringer Ingelheim, and Taisho. Tatsuya Atsumi has accepted research grants and/or honoraria for meetings from AbbVie; Alexion Pharmaceuticals; Astellas Pharma; Bristol Myers Squibb; Chugai; Daiichi Sankyo; Eisai; Eli Lilly Japan; Gilead Sciences, Inc.; Mitsubishi-Tanabe; Otsuka Pharmaceutical; Pfizer; Takeda; and UCB Japan. Daniel Aletaha reports grants or research support from AbbVie, Merck Sharp & Dohme, Novartis, and Roche; serving as a consultant for Janssen; serving on a speakers bureau for Bristol Myers Squibb, Merck Sharp & Dohme, and UCB; and serving as a consultant and on a speakers bureau for AbbVie, Amgen, Celgene, Eli Lilly, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, and Sanofi. Hendrik Schulze-Koops has research grants from AbbVie and Novartis and has received honoraria for consultancies and/or speaking engagements from AbbVie; Amgen; Bristol Myers Squibb; Celgene; Celltrion; Chugai; Gilead Sciences, Inc.; Janssen; Eli Lilly; Merck Sharp & Dohme; Novartis-Sandoz; Pfizer; Roche; and Sanofi. Haruhiko Fukada is an employee of Gilead Sciences K.K. and a shareholder of Gilead Sciences, Inc. Chris Watson is an employee of Alfasigma, Bologna, Italy. Tsutomu Takeuchi reports receiving grant/research support from AbbVie, Asahi Kasei, Astellas Pharma, Chugai, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe, Shionogi, Takeda, and UCB Japan; serving as a consultant for Astellas Pharma, Chugai, and Eli Lilly Japan; and serving on a speakers bureau for AbbVie; Ayumi Pharmaceutical Corporation; Bristol Myers Squibb; Chugai; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Eli Lilly Japan; Gilead Sciences, Inc.; Mitsubishi-Tanabe; Novartis; Pfizer Japan; and Sanofi. Yoshiya Tanaka and Tsutomu Takeuchi are editorial board members of Rheumatology and Therapy. Yoshiya Tanaka and Tsutomu Takeuchi were not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.

: The study protocols were reviewed and approved by all local institutional review boards or ethics committees of participating institutions. The studies were carried out in accordance with the Declaration of Helsinki and the International Council for Harmonisation Good Clinical Practice guidelines. All patients provided informed consent to participate. FINCH 1 was approved by the Advarra Central Institutional Review Board (reference 00000971).